A Double-Blind Placebo-Controlled Study of Intravenous Clodronate for Prevention of Steroid-Induced Bone Loss in Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 10, 2007, Pages 1184-1189

  Abitbol, Vered ^a   Briot, Karine ^a   Roux, Christian ^a   Roy, Carine ^b   Seksik, Philippe ^c   Charachon, Antoine ^b   Bouhnik, Yoram ^d   Coffin, Benoit ^e   Allez, Matthieu ^f   Lamarque, Dominique ^g   Chaussade, Stanislas ^a  

^a Hôpital Cochin ^*  (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e HÔPITAL LOUIS MOURIER   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; VITAMIN D;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; DIARRHEA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FEMUR NECK; HAIR LOSS; HEADACHE; HUMAN; INTESTINE OBSTRUCTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOLYSIS; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STEROID THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES; THORACIC VERTEBRAE; TREATMENT OUTCOME;

EID: 34848924900     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.05.016     Document Type: Article

References (47)

1. Abitbol V., Roux C., Chaussade S., et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 108 (1995) 417-422
2. Bjarnason I., Mac Pherson A., and Mackintosh C. Reduced bone density in patients with inflammatory bone density in patients with inflammatory bowel disease. Gut 40 (1997) 228-233
3. Pigot F., Roux C., Chaussade S., et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 37 (1992) 1396-1403
4. Bernstein C.N., Leslie W.D., and Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124 (2003) 795-841
5. Robinson R.J., al-Azzawi F., Iqbal S.J., et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 43 (1998) 2500-2506
6. Schoon E.J., van Nunen A.B., Wouters R.S., et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol 232 (2000) 43-47
7. Bernstein C.N., Blanchard J.F., Leslie W., et al. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 133 (2000) 795-799
8. Vestergaard P., Krogh K., Rejnmark L., et al. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 46 (2000) 176-181
9. Bernstein C.N., and Leslie W.D. Review article: osteoporosis and inflammatory bowel disease. J Bone Miner Res 10 (1995) 250-256
10. Schulte C., Dignass A.U., Mann K., et al. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 4 (1998) 268-275
11. Compston J.E. Detection of osteoporosis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 9 (1997) 931-933
12. Jahnsen J., Falch J.A., Aadland E., et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 40 (1997) 313-319
13. Gosh S., Cowen S., Hannan W.J., et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis at diagnosis. Gastroenterology 107 (1994) 1031-1039
14. Tobias J.H., Sasi M.R., Greenwood R., et al. Rapid hip bone loss in active Crohn's disease receiving short-term corticosteroid therapy. Aliment Pharmacol Ther 20 (2004) 951-957
15. Roux C., Abitbol V., Chaussade S., et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 5 (1995) 156-160
16. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 239 (1996) 131-137
17. Szulc P., and Meunier P.J. Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease?. Lancet 357 (2001) 1995-1996
18. Duggan P., O'Brien M., Kiely M., et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol 99 (2004) 2178-2185
19. Robinson R.J., Iqbal S.J., Whitaker R.P., et al. Rectal steroids suppress bone formation in patients with colitis. Aliment Pharmacol Ther 11 (1997) 201-204
20. Bernstein C.N., and Leslie W.D. Review article: osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther 19 (1996) 941-952
21. Vogelsang H., Ferenci P., Resch H., et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 7 (1995) 609-614
22. Adachi J.D., Bensen W.G., Bianchi F., et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 23 (1996) 995-1000
23. Clements D., Compston J.E., Evans W.D., et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 34 (1993) 1543-1546
24. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
25. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
26. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and the treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339 (1998) 292-299
27. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42 (1999) 2309-2318
28. Siffledeen J.S., Fedorak R.N., Siminoski K., et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 3 (2005) 122-132
29. Henderson S., Hoffman N., and Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 101 (2006) 119-123
30. Bartram S.A., Peaston R.T., Rawlings D.J., et al. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 18 (2003) 1121-1127
31. Palomba S., Orio Jr. F., Manguso F., et al. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 16 (2005) 1141-1149
32. Haderslev K.V., Tjellesen L., Sorensen H.A., et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 119 (2000) 639-646
33. Cremers S.C., van Hogezand R., Banffer D., et al. Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. Osteoporos Int 16 (2005) 1727-1730
34. Makins R., and Ballinger A. Gastrointestinal side effects of drugs. Expert Opin Drug Saf 2 (2003) 421-429
35. Adami S., Bhalla A.K., Dorizzi R., et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41 (1987) 326-331
36. Richards P.J., Amos N., Williams A.S., et al. Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo. Rheumatology 38 (1999) 984-991
37. Sims N.A., Green J.R., Glatt M., et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 50 (2004) 2338-2346
38. Richards P.J., Williams A.S., Goodfellow R.M., et al. Liposomal clodronate eliminates synovial macrophages reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology 38 (1999) 818-825
39. Filipponi P., Pedetti M., Fedeli L., et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 10 (1995) 697-703
40. McCloskey E., Selby P., Davies M., et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19 (2004) 728-736
41. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 11 (1999) 2309-2318
42. Vogelsang H., Ferenci P., Resch H., et al. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 7 (1995) 609-614
43. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15 (2000) 1006-1013
44. Van Hogezand R.A., Banffer D., Zwinderman A.H., et al. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int 17 (2006) 535-542
45. Klaus J., Armbrecht G., Steinkamp M., et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 51 (2002) 654-658
46. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44 (2001) 1496-1503
47. Chan B., and Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91 (2006) 2017-2020